Document is current

Article History

Received: 18 December 2023

Accepted: 28 December 2023

First Online: 22 February 2024

Declarations

:

: The retrospective analysis on the use of anti-seizure medications had ethical approval, and CARE guidelines were followed.

: Not applicable.

: The authors declare the following financial interests or personal relationships that may be considered competing interests: AS received personal fees and grants from Angelini Pharma, Biocodex, Desitin Arzneimittel, Eisai, Jazz (GW) Pharmaceuticals, Marinus Pharma, Precisis, Takeda, UCB (Zogenix) Pharma, and UNEEG medical. AS reports that he is part of the editorial board of <i>Neurological Research and Practice</i>. HB, LT, SH, and EH have no conflicts of interest. FR received personal fees from Angelini Pharma/Arvelle Therapeutics, Eisai GmbH, GW Pharmaceuticals/Jazz Pharma, Roche Pharma, and UCB Pharma and grants from the Detlev-Wrobel-Fonds for Epilepsy Research, the Deutsche Forschungsgemeinschaft (DFG), the Federal Ministry of Education and Research (BMBF), the LOEWE Programme of the State of Hesse, and the European Union. FR reports that he is part of the editorial board of <i>Neurological Research and Practice</i>. CM reports speakers’ honoraria from Eisai and UCB and travel support from Jazz Pharmaceuticals.